NYSE:EBS Emergent BioSolutions (EBS) Stock Price, News & Analysis $7.52 -0.11 (-1.44%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$7.32▼$7.7750-Day Range$5.72▼$14.7952-Week Range$1.42▼$15.10Volume1.33 million shsAverage Volume3.84 million shsMarket Capitalization$394.06 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Emergent BioSolutions alerts: Email Address Emergent BioSolutions MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside59.6% Upside$12.00 Price TargetShort InterestHealthy6.83% of Float Sold ShortDividend StrengthN/ASustainability-1.40Upright™ Environmental ScoreNews Sentiment0.52Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.82 out of 5 starsMedical Sector197th out of 910 stocksPharmaceutical Preparations Industry79th out of 426 stocks 3.2 Analyst's Opinion Consensus RatingEmergent BioSolutions has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEmergent BioSolutions has only been the subject of 2 research reports in the past 90 days.Read more about Emergent BioSolutions' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.83% of the float of Emergent BioSolutions has been sold short.Short Interest Ratio / Days to CoverEmergent BioSolutions has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Emergent BioSolutions has recently decreased by 6.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEmergent BioSolutions does not currently pay a dividend.Dividend GrowthEmergent BioSolutions does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEmergent BioSolutions has received a 73.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Influenza vaccines", "Cholera vaccines", and "Antibiotics" products. See details.Environmental SustainabilityThe Environmental Impact score for Emergent BioSolutions is -1.40. Previous Next 2.0 News and Social Media Coverage News SentimentEmergent BioSolutions has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Emergent BioSolutions this week, compared to 3 articles on an average week.Search Interest35 people have searched for EBS on MarketBeat in the last 30 days. This is an increase of 52% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Emergent BioSolutions to their MarketBeat watchlist in the last 30 days. This is a decrease of -59% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Emergent BioSolutions insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Emergent BioSolutions is held by insiders.Percentage Held by Institutions78.40% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Emergent BioSolutions' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Emergent BioSolutions is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Emergent BioSolutions is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEmergent BioSolutions has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Emergent BioSolutions' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Emergent BioSolutions Stock (NYSE:EBS)Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Read More EBS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EBS Stock News HeadlinesSeptember 3, 2024 | globenewswire.comEmergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial ProfileAugust 30, 2024 | msn.comEmergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox VaccineSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 30, 2024 | markets.businessinsider.comEmergent's Smallpox Vaccine For Mpox Receives FDA ApprovalAugust 30, 2024 | markets.businessinsider.comEmergent BioSolutions' ACAM2000 Gets FDA Approval For Mpox Indication; Stock UpAugust 30, 2024 | seekingalpha.comEmergent stock jumps as FDA clears smallpox vaccine for people at high risk of mpoxAugust 30, 2024 | globenewswire.comEmergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency PreparednessAugust 30, 2024 | benzinga.comMpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox InfectionSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 30, 2024 | barrons.comEmergent BioSolutions Stock Soars as FDA Approves Mpox VaccineAugust 29, 2024 | ca.finance.yahoo.comEBS Aug 2024 11.000 callAugust 29, 2024 | ca.finance.yahoo.comEBS Aug 2024 9.000 putAugust 29, 2024 | reuters.comUS FDA approves use of Emergent's smallpox vaccine for people at high risk of mpoxAugust 29, 2024 | globenewswire.comEmergent BioSolutions' ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other RegionsAugust 29, 2024 | ca.finance.yahoo.comEBS Sep 2024 9.000 callAugust 28, 2024 | americanbankingnews.comEmergent BioSolutions (NYSE:EBS) Receives New Coverage from Analysts at Rodman & RenshawAugust 28, 2024 | americanbankingnews.comEmergent BioSolutions (NYSE:EBS) Coverage Initiated at Rodman & RenshawAugust 26, 2024 | reuters.comEmergent to cut up to 70 roles at Lansing facilitySee More Headlines Receive EBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)12/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNYSE:EBS CUSIP29089Q10 CIK1367644 Webwww.emergentbiosolutions.com Phone(240) 631-3200Fax301-795-1899Employees1,600Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$16.00 Low Stock Price Target$8.00 Potential Upside/Downside+59.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($11.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-760,500,000.00 Net Margins-53.26% Pretax Margin-52.45% Return on Equity-34.38% Return on Assets-11.71% Debt Debt-to-Equity Ratio1.16 Current Ratio1.06 Quick Ratio0.54 Sales & Book Value Annual Sales$1.07 billion Price / Sales0.37 Cash Flow$0.79 per share Price / Cash Flow9.46 Book Value$7.30 per share Price / Book1.03Miscellaneous Outstanding Shares52,402,000Free Float51,773,000Market Cap$394.06 million OptionableOptionable Beta1.60 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Richard S. Lindahl M.B.A. (Age 60)Executive VP, CFO & Treasurer Comp: $1.02MMs. Jennifer L. Fox (Age 51)Executive VP of External Affairs, General Counsel & Corporate Secretary Comp: $975.84kMs. Coleen Glessner (Age 53)Executive Vice President of Global Quality and Ethics & Compliance Comp: $959.37kMr. Paul A. Williams (Age 57)Senior Vice President of Products Business Comp: $846.97kMr. Joseph C. Papa Jr. (Age 68)CEO, President & Director Michelle PepinSenior VP & Chief Human Resource OfficerMs. Stephanie DuatschekSenior VP, Chief Strategy & Transformation OfficerDr. Kelly Lyn WarfieldSenior VP of Science & DevelopmentWilliam HartzelSenior Vice President of Manufacturing & BioservicesMore ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXInnovivaNASDAQ:INVAOPKO HealthNASDAQ:OPKIronwood PharmaceuticalsNASDAQ:IRWDLexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsTruist Financial CorpBought 14,360 shares on 8/21/2024Ownership: 0.251%Millennium Management LLCBought 52,144 shares on 8/15/2024Ownership: 1.806%AQR Capital Management LLCSold 591,387 shares on 8/15/2024Ownership: 0.878%Susquehanna Fundamental Investments LLCSold 19,393 shares on 8/15/2024Ownership: 0.189%Point72 Asia Singapore Pte. Ltd.Bought 71,078 shares on 8/15/2024Ownership: 0.136%View All Insider TransactionsView All Institutional Transactions EBS Stock Analysis - Frequently Asked Questions How have EBS shares performed this year? Emergent BioSolutions' stock was trading at $2.40 at the beginning of 2024. Since then, EBS shares have increased by 213.3% and is now trading at $7.52. View the best growth stocks for 2024 here. How were Emergent BioSolutions' earnings last quarter? Emergent BioSolutions Inc. (NYSE:EBS) released its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($2.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by $1.35. The biopharmaceutical company earned $254.70 million during the quarter, compared to the consensus estimate of $199.47 million. Emergent BioSolutions had a negative net margin of 53.26% and a negative trailing twelve-month return on equity of 34.38%. What is Bob Kramer's approval rating as Emergent BioSolutions' CEO? 38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees. Who are Emergent BioSolutions' major shareholders? Top institutional investors of Emergent BioSolutions include Millennium Management LLC (1.81%), American Century Companies Inc. (1.68%), Marshall Wace LLP (1.04%) and Whitebox Advisors LLC. Insiders that own company stock include Kathryn C Zoon, Ronald Richard and Richard S Lindahl. View institutional ownership trends. How do I buy shares of Emergent BioSolutions? Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Emergent BioSolutions own? Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX) and Gilead Sciences (GILD). This page (NYSE:EBS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent BioSolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EBS Stock Alerts